Expanding diversity in molecular structures and functions of the IL-6/IL-12 heterodimeric cytokine family

Frontiers in Immunology

Volumn 7, Issue NOV, 2016, Pages

  Hasegawa, Hideaki ^a   Mizoguchi, Izuru ^a   Chiba, Yukino ^a   Ohashi, Mio ^a   Xu, Mingli ^a   Yoshimoto, Takayuki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

IL 12; IL 23; IL 27; IL 30; IL 35; IL 39; IL 6; IL Y

Indexed keywords

CONCANAVALIN A; CYTOKINE; CYTOKINE LIKE FACTOR; EPSTEIN BARR VIRUS INDUCED PROTEIN 3; GAMMA INTERFERON; HETERODIMER; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 27P28; INTERLEUKIN 30; INTERLEUKIN 35; INTERLEUKIN 39; INTERLEUKIN 6; PROTEIN P28; PROTEIN P40; STAT PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRAL PROTEIN;

ALTERNATIVE RNA SPLICING; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTRACELLULAR SIGNALING; LIVER FIBROSIS; LYMPHOCYTE ACTIVATION; MALARIA; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; UPREGULATION;

EID: 85006154160     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00479     Document Type: Review

References (77)

1. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 13(8):722-8. doi: 10.1038/ni.2366
2. Garbers C, Hermanns HM, Schaper F, Muller-Newen G, Grotzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 23(3):85-97. doi:10.1016/j.cytogfr.2012.04.001
3. Belladonna ML, Grohmann U. Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnol Genet Eng Rev (2013) 29:149-74. doi:10.1080/02648725.2013.801228
4. Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev (2015) 26(5):475-87. doi:10.1016/j.cytogfr.2015.07.004
5. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 1813(5):878-88. doi:10.1016/j.bbamcr.2011.01.034
6. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 16:495-521. doi:10.1146/annurev.immunol.16.1.495
7. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 3(2):133-46. doi:10.1038/nri1001
8. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 13(5):715-25. doi:10.1016/S1074-7613(00)00070-4
9. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol (2007) 28(1):33-8. doi:10.1016/j.it.2006.11.002
10. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med (2015) 21(7):719-29. doi:10.1038/nm.3895
11. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol (2015) 33:417-43. doi:10.1146/annurev-immunol-032414-112134
12. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450(7169):566-9. doi:10.1038/nature06306
13. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 13(3):290-9. doi:10.1038/ni.2227
14. Wang X, Wei Y, Xiao H, Liu X, Zhang Y, Han G, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in lupus-like mice. Eur J Immunol (2016) 46(6):1343-50. doi:10.1002/eji.201546095
15. Wang RX, Yu CR, Mahdi RM, Egwuagu CE. Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem (2012) 287(43):36012-21. doi:10.1074/jbc.M112.390625
16. Flores RR, Kim E, Zhou L, Yang C, Zhao J, Gambotto A, et al. IL-Y, a synthetic member of the IL-12 cytokine family, suppresses the development of type 1 diabetes in NOD mice. Eur J Immunol (2015) 45(11):3114-25. doi:10.1002/eji.201445403
17. Yan J, Mitra A, Hu J, Cutrera JJ, Xia X, Doetschman T, et al. Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cells. J Hepatol (2016) 64(5):1128-36. doi:10.1016/j.jhep.2015.12.020
18. Kudo H, Wang Z, Jinnin M, Nakayama W, Inoue K, Honda N, et al. EBI3 downregulation contributes to type I collagen overexpression in scleroderma skin. J Immunol (2015) 195(8):3565-73. doi:10.4049/jimmunol.1402362
19. Espigol-Frigole G, Planas-Rigol E, Ohnuki H, Salvucci O, Kwak H, Ravichandran S, et al. Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Sci Signal (2016) 9(419):ra28. doi:10.1126/scisignal.aad2357
20. Dietrich C, Candon S, Ruemmele FM, Devergne O. A soluble form of IL-27Ralpha is a natural IL-27 antagonist. J Immunol (2014) 192(11):5382-9. doi:10.4049/jimmunol.1303435
21. Franke M, Schroder J, Monhasery N, Ackfeld T, Hummel TM, Rabe B, et al. Human and murine interleukin 23 receptors are novel substrates for a disintegrin and metalloproteases ADAM10 and ADAM17. J Biol Chem (2016) 291(20):10551-61. doi:10.1074/jbc.M115.710541
22. Hunter CA, Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity (2012) 37(6):960-9. doi:10.1016/j.immuni.2012.11.003
23. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 16(6):779-90. doi:10.1016/S1074-7613(02)00324-2
24. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 172(4):2225-31. doi:10.4049/jimmunol.172.4.2225
25. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early regulation of Th1 differentiation. J Immunol (2005) 175(4):2191-200. doi:10.4049/jimmunol.175.4.2191
26. Owaki T, Asakawa M, Fukai F, Mizuguchi J, Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet-and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J Immunol (2006) 177(11):7579-87. doi:10.4049/jimmunol.177.11.7579
27. Owaki T, Asakawa M, Morishima N, Mizoguchi I, Fukai F, Takeda K, et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol (2008) 180(5):2903-11. doi:10.4049/jimmunol.180.5.2903
28. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 8(12):1380-9. doi:10.1038/ni1541
29. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity (2003) 19(5):645-55. doi:10.1016/S1074-7613(03)00300-5
30. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, Takeda A, et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity (2003) 19(5):657-67. doi:10.1016/S1074-7613(03)00298-X
31. Pot C, Apetoh L, Awasthi A, Kuchroo VK. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol (2011) 23(6):438-45. doi:10.1016/j.smim.2011.08.003
32. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol (2011) 23(3):202-8. doi:10.1016/j.smim.2011.07.005
33. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol (1996) 157(2):798-805.
34. Findlay EG, Greig R, Stumhofer JS, Hafalla JC, de Souza JB, Saris CJ, et al. Essential role for IL-27 receptor signaling in prevention of Th1-mediated immunopathology during malaria infection. J Immunol (2010) 185(4):2482-92. doi:10.4049/jimmunol.0904019
35. Freitas do Rosario AP, Lamb T, Spence P, Stephens R, Lang A, Roers A, et al. IL-27 promotes IL-10 production by effector Th1 CD4+ T cells: a critical mechanism for protection from severe immunopathology during malaria infection. J Immunol (2012) 188(3):1178-90. doi:10.4049/jimmunol.1102755
36. Villegas-Mendez A, de Souza JB, Lavelle SW, Gwyer Findlay E, Shaw TN, van Rooijen N, et al. IL-27 receptor signalling restricts the formation of pathogenic, terminally differentiated Th1 cells during malaria infection by repressing IL-12 dependent signals. PLoS Pathog (2013) 9(4):e1003293. doi:10.1371/journal.ppat.1003293
37. Ho M, Webster HK, Green B, Looareesuwan S, Kongchareon S, White NJ. Defective production of and response to IL-2 in acute human falciparum malaria. J Immunol (1988) 141(8):2755-9.
38. Kimura D, Miyakoda M, Kimura K, Honma K, Hara H, Yoshida H, et al. Interleukin-27-producing CD4(+) T cells regulate protective immunity during malaria parasite infection. Immunity (2016) 44(3):672-82. doi:10.1016/j.immuni.2016.02.011
39. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood (2012) 119(13):2991-3002. doi:10.1182/blood-2011-12-380113
40. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol (2014) 14(5):302-14. doi:10.1038/nri3660
41. Seita J, Asakawa M, Ooehara J, Takayanagi S, Morita Y, Watanabe N, et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood (2008) 111(4):1903-12. doi:10.1182/blood-2007-06-093328
42. Furusawa J, Mizoguchi I, Chiba Y, Hisada M, Kobayashi F, Yoshida H, et al. Promotion of expansion and differentiation of hematopoietic stem cells by interleukin-27 into myeloid progenitors to control infection in emergency myelopoiesis. PLoS Pathog (2016) 12(3):e1005507. doi:10.1371/journal.ppat.1005507
43. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, et al. Potent antitumor activity of interleukin-27. Cancer Res (2004) 64(3):1152-6. doi:10.1158/0008-5472.CAN-03-2084
44. Yoshimoto T, Chiba Y, Furusawa JI, Xu M, Tsunoda R, Higuchi K, et al. Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci (2015) 106(9):1103-10. doi:10.1111/cas.12731
45. Mizoguchi I, Chiba Y, Furusawa JI, Xu M, Tsunoda R, Higuchi K, et al. Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. Oncoimmunology (2015) 4(10):e1042200. doi:10.1080/2162402X.2015.1042200
46. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res (2011) 71(23):7168-75. doi:10.1158/0008-5472.CAN-11-0459
47. Dibra D, Mitra A, Newman M, Xia X, Cutrera JJ, Gagea M, et al. Lack of immunomodulatory interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clin Cancer Res (2016) 22(15):3876-83. doi:10.1158/1078-0432.CCR-15-2052
48. Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology (2016) 63(3):1000-12. doi:10.1002/hep.28379
49. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 11(12):1093-101. doi:10.1038/ni.1952
50. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med (2014) 20(6):633-41. doi:10.1038/nm.3554
51. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature (2014) 507(7492):366-70. doi:10.1038/nature12979
52. Fijak M, Meinhardt A. The testis in immune privilege. Immunol Rev (2006) 213:66-81. doi:10.1111/j.1600-065X.2006.00438.x
53. Li N, Wang T, Han D. Structural, cellular and molecular aspects of immune privilege in the testis. Front Immunol (2012) 3:152. doi:10.3389/fimmu.2012.00152
54. Terayama H, Yoshimoto T, Hirai S, Naito M, Qu N, Hatayama N, et al. Contribution of IL-12/IL-35 common subunit p35 to maintaining the testicular immune privilege. PLoS One (2014) 9(4):e96120. doi:10.1371/journal.pone.0096120
55. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol (2013) 190(5):2415-23. doi:10.4049/jimmunol.1202535
56. Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity (2016) 44(2):316-29. doi:10.1016/j.immuni.2016.01.013
57. Wang X, Liu X, Zhang Y, Wang Z, Zhu G, Han G, et al. IL-39 (IL-23p19/Ebi3) induces differentiation/expansion of neutrophils in lupus-prone mice. Clin Exp Immunol (2016) 186(2):144-56. doi:10.1111/cei.12840
58. Ramnath D, Tunny K, Hohenhaus DM, Pitts CM, Bergot AS, Hogarth PM, et al. TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytes. Immunol Cell Biol (2015) 93(9):771-9. doi:10.1038/icb.2015.77
59. Lin Q, Fang D, Fang J, Ren X, Yang X, Wen F, et al. Impaired wound healing with defective expression of chemokines and recruitment of myeloid cells in TLR3-deficient mice. J Immunol (2011) 186(6):3710-7. doi:10.4049/jimmunol.1003007
60. Stumhofer JS, Tait ED, Quinn WJ III, Hosken N, Spudy B, Goenka R, et al. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 11(12):1119-26. doi:10.1038/ni.1957
61. Crabe S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, et al. The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J Immunol (2009) 183(12):7692-702. doi:10.4049/jimmunol.0901464
62. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Holscher C, et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 receptor homodimer. J Biol Chem (2013) 288(6):4346-54. doi:10.1074/jbc.M112.432955
63. Tormo AJ, Letellier MC, Lissilaa R, Batraville LA, Sharma M, Ferlin W, et al. The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities. Cytokine (2012) 60(3):653-60. doi:10.1016/j.cyto.2012.08.014
64. Tormo AJ, Meliani Y, Beaupre LA, Sharma M, Fritz JH, Elson G, et al. The composite cytokine p28/cytokine-like factor 1 sustains B cell proliferation and promotes plasma cell differentiation. J Immunol (2013) 191(4):1657-65. doi:10.4049/jimmunol.1201595
65. Dibra D, Cutrera J, Xia X, Kallakury B, Mishra L, Li S. Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury. Hepatology (2012) 55(4):1204-14. doi:10.1002/hep.24814
66. Zhang S, Liang R, Luo W, Liu C, Wu X, Gao Y, et al. High susceptibility to liver injury in IL-27 p28 conditional knockout mice involves intrinsic interferon-gamma dysregulation of CD4+ T cells. Hepatology (2013) 57(4):1620-31. doi:10.1002/hep.26166
67. Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology (2014) 60(6):2027-39. doi:10.1002/hep.27392
68. Di Meo S, Airoldi I, Sorrentino C, Zorzoli A, Esposito S, Di Carlo E. Interleukin-30 expression in prostate cancer and its draining lymph nodes correlates with advanced grade and stage. Clin Cancer Res (2014) 20(3):585-94. doi:10.1158/1078-0432.CCR-13-2240
69. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol (1996) 70(2):1143-53.
70. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res (2011) 17(19):6272-86. doi:10.1158/1078-0432.CCR-11-0060
71. Trojanowska M, LeRoy EC, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med (Berl) (1998) 76(3-4):266-74. doi:10.1007/s001090050216
72. Li MF, Sun BG, Xiao ZZ, Sun L. First characterization of a teleost Epstein-Barr virus-induced gene 3 (EBI3) reveals a regulatory effect of EBI3 on the innate immune response of peripheral blood leukocytes. Dev Comp Immunol (2013) 41(4):514-22. doi:10.1016/j.dci.2013.07.022
73. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet (2008) 372(9634):234-45. doi:10.1016/S0140-6736(08)61077-6
74. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683-765. doi:10.1146/annurev.immunol.19.1.683
75. Aparicio-Siegmund S, Moll JM, Lokau J, Grusdat M, Schroder J, Plohn S, et al. Recombinant p35 from bacteria can form Interleukin (IL-)12, but not IL-35. PLoS One (2014) 9(9):e107990. doi:10.1371/journal.pone.0107990
76. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature (2001) 409(6822):860-921. doi:10.1038/35057062
77. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science (2001) 291(5507):1304-51. doi:10.1126/science.1058040